These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2527545)

  • 1. Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and beta-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients.
    Belz GG; Essig J; Erb K; Breithaupt K; Hoogkamer JF; Kneer J; Kleinbloesem CH
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):317S-322S. PubMed ID: 2527545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemodynamic and hormonal effects of cilazapril in comparison with propranolol in healthy subjects and in hypertensive patients.
    Kleinbloesem CH; Erb K; Essig J; Breithaupt K; Belz GG
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):309S-315S. PubMed ID: 2527544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex.
    Belz GG; Essig J; Kleinbloesem CH; Hoogkamer JF; Wiegand UW; Wellstein A
    Br J Clin Pharmacol; 1988 Nov; 26(5):547-56. PubMed ID: 2974715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol.
    Erb KA; Essig J; Breithaupt K; Belz GG
    Drugs; 1991; 41 Suppl 1():11-7. PubMed ID: 1712266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the combination of cilazapril and propranolol lower blood pressure at rest and during exercise more pronouncedly than either of the two components given alone?
    Erb KA; Breithaupt K; Kleinbloesem CH; Wolf GK; Belz GG
    Clin Physiol Biochem; 1990; 8 Suppl 2():35-45. PubMed ID: 2151315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise, and ambulatory blood pressure.
    White WB; McCabe EJ; Hager WD; Schulman P
    Clin Pharmacol Ther; 1988 Aug; 44(2):173-8. PubMed ID: 2969315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor.
    Rosendorff C; Patton J; Radford HM; Kalliatakis B
    J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S105-9. PubMed ID: 1382157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of studies on the clinical pharmacodynamics of cilazapril.
    Belz GG; Breithaupt K; Erb K
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S14-9. PubMed ID: 7898090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and effects on renal function following cilazapril and hydrochlorothiazide alone and in combination in healthy subjects and hypertensive patients.
    Nilsen OG; Sellevold OF; Romfo OS; Smedsrud A; Grynne B; Williams PE; Kleinbloesem CH
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):323S-328S. PubMed ID: 2527546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of prostaglandin inhibition by indomethacin on blood pressure and renal function in hypertensive patients treated with cilazapril.
    Kirch W; Stroemer K; Hoogkamer JF; Kleinbloesem CH
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):297S-301S. PubMed ID: 2527542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta-blocker propranolol and their combination on haemodynamics in hypertension.
    Belz GG; Breithaupt K; Erb K; Kleinbloesem CH; Wolf GK
    J Hypertens; 1989 Oct; 7(10):817-24. PubMed ID: 2531184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of cilazapril, a new angiotensin converting enzyme inhibitor, on peak and trough blood pressure measurements in hypertensive patients.
    Güntzel P; Kobrin I; Pasquier C; Zimlichman R; Viskoper JR
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):8-12. PubMed ID: 1708060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.
    Deget F; Brogden RN
    Drugs; 1991 May; 41(5):799-820. PubMed ID: 1712710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of single and consecutive doses of cilazapril and its depressor effects in patients with essential hypertension.
    Shionoiri H; Gotoh E; Miyakawa T; Takasaki I; Oda H; Ueda S; Kaneko Y
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):269S-273S. PubMed ID: 2970854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive effect of cilazapril in essential hypertensive patients. Clinical study with 24 h ambulatory blood pressure monitoring.
    Hiwatari M; Abe K; Yoshinaga K; Saito T
    Arzneimittelforschung; 1991 Nov; 41(11):1137-40. PubMed ID: 1839765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal or impaired renal function.
    Shionoiri H; Gotoh E; Sugimoto K; Takasaki I; Minamisawa K; Ishii M
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):283S-287S. PubMed ID: 2527540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of 2.5 and 5 mg cilazapril versus placebo on daily blood pressure load.
    Poirier L; Pyzyk M; Provencher P; Lacourcière Y
    Am J Hypertens; 1991 Nov; 4(11):913-5. PubMed ID: 1838693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive treatment with cilazapril. Resting and exercise blood pressure, hormones and enzymes.
    Breithaupt K; Belz GG; Spielmanns DG; Neis W; Kirchner P
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):136-41. PubMed ID: 2159308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of metoprolol and cilazapril on blood pressure and on sleep apnea activity.
    Mayer J; Weichler U; Herres-Mayer B; Schneider H; Marx U; Peter JH
    J Cardiovasc Pharmacol; 1990 Dec; 16(6):952-61. PubMed ID: 1704989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension.
    Ajayi AA; Elliott HL; Reid JL
    Br J Clin Pharmacol; 1986 Aug; 22(2):167-75. PubMed ID: 3019375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.